Grail is making some headway in its mission to develop a liquid biopsy solution to detect cancer early. The Menlo Park, CA-based company said it has initiated PATHFINDER, a multi-center study.
PATHFINDER will mark the first time Grail’s test results will be returned to healthcare providers and communicated to participants to help guide appropriate diagnostic workups for more than 50 cancer types.
“Grail is at the forefront of transforming early cancer detection as we bring our multi-cancer test into clinical practice through our first interventional study,” Hans Bishop, CEO at Grail in a release. “We are partnering with leading healthcare systems to gain important real-world insight into the clinical use of our multi-cancer early detection test, an important step on our path toward commercialization.”
The PATHFINDER Study is conducted under an IDE to evaluate Grail’s multi-cancer early detection test. The test will enroll about 6,200 participants across several health systems and is sponsored by Grail.
Grail hit a major milestone last year when it was granted a Break Through Device Designation by FDA. But the company has been making strides since it was spun out from Illumina in 2016. From record-breaking financing rounds to establishing massive clinical trials, the company has been at the forefront of the liquid biopsy market.
